ReviewFrontiers in endocrinology2024
Serum uric acid and nonalcoholic fatty liver disease.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- NAFLD-related SNPs are linked to changes in liver fat, as measured by the CAP score, and serum lipids in response to a 3-week sugar-sweetened beverage intervention: a pilot study.Food & function · 2026Trial
- An interpretable machine learning model based on routine clinical indicators for early identification of obesity-related non-alcoholic fatty liver disease in children: a single-center retrospective study.Translational pediatrics · 2026Article
- Uric Acid-to-HDL cholesterol ratio and probable MASLD across adiposity strata in postmenopausal women.Metabolism open · 2026Article
- Application of Multivariate Adaptive Regression Splines to Estimate Fatty Liver Index in Healthy Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2026Article
- Synergistic Impact of Fasting Plasma Glucose and Serum Uric Acid on Peripheral Diabetic Retinopathy Severity in T2DM Patients.Translational vision science & technology · 2026Article
- 4-phenylbutyric acid attenuates hepatic ER stress, pyroptosis, and NAFLD in adult rat offspring exposed to a high-fat, high-fructose diet during perinatal and adulthood.Lipids in health and disease · 2026Article
- The Influence of Acute Cold Stress on Intestinal Health of the Juvenile Chinese Soft-Shelled Turtle (Animals : an open access journal from MDPI · 2026Article
- Uric acid and hyperuricemia in relation to non-alcoholic fatty liver disease among individuals with type 2 diabetes: insights from a cross-sectional analysis.Frontiers in endocrinology · 2026Article
- Life-course BMI trajectories and long-term weight gain in relation to hepatic steatosis in a rural community-based cohort in Southwest China.Frontiers in public health · 2026Article
- Association between uric acid and non-alcoholic fatty liver disease in patients with hypertension.PloS one · 2026Article
- From soluble uric acid to sodium urate crystal: immune metabolic inflammation driven by uric acid morphological transformation and mechanism-oriented therapy.Frontiers in immunology · 2026Review
- Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- The ratio of serum uric acid to high-density lipoprotein cholesterol as a predictor for frailty prevalence and mortality in the elderly U.S. adults.Lipids in health and disease · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Children with Obesity: Sex-Stratified Analysis of Hepatic Enzyme Profiles and Serum Uric Acid.Healthcare (Basel, Switzerland) · 2025Article
- Is UA/HDL-C a Reliable Surrogate Marker for Fatty Liver? A Comparative Evaluation with Metabolic Scores in a Mexican Population: The Genetics of Atherosclerotic Disease Study.Diagnostics (Basel, Switzerland) · 2025Article
- Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by over 5% hepatic fat accumulation without secondary causes. The prevalence of NAFLD has escalated in recent years due to shifts in dietary patterns and socioeconomic status, making it the most prevalent chronic liver disease and a significant public health concern globally. Serum uric acid (SUA) serves as the end product of purine metabolism in the body and is intricately linked to metabolic syndrome. Elevated SUA levels have been identified as an independent risk factor for the incidence and progression of NAFLD. This paper reviews the relationship between SUA and NAFLD, the underlying mechanisms of SUA involved in NAFLD, and the potential benefits of SUA-lowering therapy in treating NAFLD. The aim is to raise awareness of SUA management in patients with NAFLD, and to encourage further investigation into pharmacological interventions in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.